Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| GLOBAL GEOPH | GGS | 7.79% |
| STAAR SURGIC | STAA | 6.23% |
| KAPSTONE PAP | KS | 6.14% |
| HORNBECK OFF | HOS | 5.99% |
| ANIKA THERAP | ANIK | 5.55% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
AmerisourceBergen Corporation’s (ABC - Analyst Report) third quarter fiscal 2012 (ended June 30, 2012) earnings (excluding employee severance and acquisition costs) of 72 cents per share beat the Zacks Consensus Estimate of 69 cents and the year-ago earnings by 9%. A lower share count aided earnings in the third quarter of fiscal 2012.
Total revenue for the third quarter slipped 1.9% to $19.8 billion. Revenues fell short of the Zacks Consensus Estimate of $20.3 billion.
Quarter in Details
Following the acquisition of World Courier Group earlier in the year, AmerisourceBergen made some adjustments in its reporting format. The company decided to report results of the AmerisourceBergen Drug Corporation (ABDC), AmerisourceBergen Specialty Group (ABSG) units under the Pharmaceutical Distribution segment. Results of the World Courier Group and AmerisourceBergen Consulting Services (ABCS) have been clubbed under the “Other” head from this quarter.
The decline in total revenues in the reported quarter was primarily attributable to the disappointing performance of the ABDC unit, where sales slipped 5%. Sales were hurt by lower volumes.
Revenues from the Pharmaceutical Distribution segment, which accounted for 98% of total revenues, slipped 3% to $19.4 billion during the reported quarter.
The ABSG unit performed well during the quarter with sales climbing 8%. Results of the segment were boosted by growth in third party logistics and vaccine and physician office distribution business at AmerisourceBergen. Revenues were boosted 1.5% by AmerisourceBergen’s acquisitions of World Courier and CVS Caremark Corporation’s (CVS - Analyst Report) subsidiary TheraCom.
Gross profit for the quarter climbed 5.4% to $689.2 million. Gross profit was boosted by AmerisourceBergen’s recent acquisitions and the encouraging performance of generic pharmaceuticals.
Operating expenses during the quarter climbed 11.6% to $375.5 million. The increase was primarily attributable to acquisition-related expenses and increased depreciation and amortization costs.
The quarter saw AmerisourceBergen buy back shares worth $186 million. The company has brought back shares worth $514 million in the first nine months of fiscal 2012.
We note that in May 2012, AmerisourceBergen authorized an additional share repurchase program of $750 million, having completed the earlier $750 million share buyback program – this should help boost the bottom line. We believe that the buyback program highlights the company’s commitment to return value for shareholders.
Fiscal 2012 Earnings Outlook Narrowed
Apart from releasing third quarter results, AmerisourceBergen narrowed its projected earnings range for fiscal 2012 to $2.80-$2.84 from $2.74-$2.84. The Zacks Consensus Estimate of $2.81 is towards the lower end of the company’s new guidance range.
AmerisourceBergen continues to project flat-to-modest revenue growth. The company continues to expect operating margin to grow in the high single-digit basis points range. Free cash flow, which includes capital expenditures of approximately $200 million, is expected in the range of $800- $900 million.
Our Recommendation
We currently have a Neutral recommendation on AmerisourceBergen. The stock carries a Zacks #3 Rank (Hold) in the short-run.
Get the full Analyst Report on ABC - FREE
Get the full Analyst Report on CVS - FREE